Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Aerosolised prostacyclin for pulmonary hypertension in neonates.

Literature DB >> 7820721

Aerosolised prostacyclin for pulmonary hypertension in neonates.

Abstract

Aerosolised prostacyclin (PGI2) was administered to two neonates with pulmonary hypertension to dilate the pulmonary vessels selectively. The alveolar-arterial oxygen gradient fell from 73.2 (patient 1) and 71.8 kPa (patient 2) to 33.8 and 26.7 kPa respectively. Systemic blood pressure remained stable while pulmonary blood pressure declined in patient 1. When inhaled, PGI2 seems to improve oxygenation, mainly due to reduction of intrapulmonary shunting.

Entities: Chemical Disease Species

Mesh：

Substances：
Aerosols
Epoprostenol

Year: 1994 PMID： 7820721 PMCID： PMC1061130 DOI： 10.1136/fn.71.3.f214

Source DB: PubMed Journal: Arch Dis Child Fetal Neonatal Ed ISSN： 1359-2998 Impact factor: 5.747

6 in total

1. Aerosolised prostacyclin in adult respiratory distress syndrome.

Authors: D Walmrath; T Schneider; J Pilch; F Grimminger; W Seeger
Journal: Lancet Date: 1993-10-16 Impact factor: 79.321

2. PGI2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction.

Authors: M Welte; B Zwissler; H Habazettl; K Messmer
Journal: Eur Surg Res Date: 1993 Impact factor: 1.745

3. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn.

Authors: J D Roberts; D M Polaner; P Lang; W M Zapol
Journal: Lancet Date: 1992-10-03 Impact factor: 79.321

4. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass.

Authors: D L Wessel; I Adatia; T M Giglia; J E Thompson; T J Kulik
Journal: Circulation Date: 1993-11 Impact factor: 29.690

5. Inhaled nitric oxide for the adult respiratory distress syndrome.

Authors: R Rossaint; K J Falke; F López; K Slama; U Pison; W M Zapol
Journal: N Engl J Med Date: 1993-02-11 Impact factor: 91.245

6. Bronchoconstrictor and antibronchoconstrictor properties of inhaled prostacyclin in asthma.

Authors: C C Hardy; P Bradding; C Robinson; S T Holgate
Journal: J Appl Physiol (1985) Date: 1988-04

6 in total

21 in total

Review 1. Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents.

Authors: Nicolas F M Porta; Robin H Steinhorn
Journal: Clin Perinatol Date: 2012-03 Impact factor: 3.430

Review 2. Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management.

Authors: Enrique M Ostrea; Esterlita T Villanueva-Uy; Girija Natarajan; Herbert G Uy
Journal: Paediatr Drugs Date: 2006 Impact factor: 3.022

3. Improvement of oxygenation induced by aerosolized prostacyclin in a preterm infant with persistent pulmonary hypertension of the newborn.

Authors: V Soditt; C Aring; P Groneck
Journal: Intensive Care Med Date: 1997-12 Impact factor: 17.440

4. Eight hours' inhalation of prostacyclin (PGI2) in healthy lambs: effects on tracheal, bronchial, and alveolar morphology.

Authors: O Habler; M Kleen; S Takenaka; R Leiderer; R Pusch; M Welte; B Zwissler; K Messmer
Journal: Intensive Care Med Date: 1996-11 Impact factor: 17.440

Aerosolised prostacyclin for pulmonary hypertension in neonates.

1. Aerosolised prostacyclin in adult respiratory distress syndrome.

2. PGI2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction.

3. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn.

4. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass.

5. Inhaled nitric oxide for the adult respiratory distress syndrome.

6. Bronchoconstrictor and antibronchoconstrictor properties of inhaled prostacyclin in asthma.

Review 1. Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents.

Review 2. Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management.

3. Improvement of oxygenation induced by aerosolized prostacyclin in a preterm infant with persistent pulmonary hypertension of the newborn.

4. Eight hours' inhalation of prostacyclin (PGI2) in healthy lambs: effects on tracheal, bronchial, and alveolar morphology.

Review 5. Pharmacotherapy for pulmonary hypertension.

Review 6. The future potential of eicosanoids and their inhibitors in paediatric practice.

7. Effect of increasing doses of magnesium in experimental pulmonary hypertension after acute pulmonary embolism.

8. Inhalation of prostacyclin (PGI2) for 8 hours does not produce signs of acute pulmonary toxicity in healthy lambs.

9. Diagnosis and treatment of pulmonary hypertension in infancy.

10. Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the newborn.